Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Musculoskeletal  |  Neurology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Multiple Sclerosis Clinical Trials

A listing of Multiple Sclerosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (111) clinical trials

Biomarkers of Synaptic Damage in Multiple Sclerosis

Blood and cerebrospinal fluid samples will be subjected to the procedures required for the isolation of the different components immediately after the withdrawal. Subsequently, the levels of microRNAs, cytokines, chemokines, cell growth factors, neuronal damage markers (tau, phosphorylated and truncated tau, neurofilaments) and mitochondrial (lactate) and free d-amino acids (Objective ...

Phase N/A

Alzheimer's Disease Genetics Study

The purpose of the Alzheimer's Disease Genetics Study is to help identify the genes that may be responsible for causing Alzheimer's Disease (AD) by collecting genetic material from families with multiple members diagnosed with AD. Qualifying families will have two living blood-related individuals who have been diagnosed with or are ...

Phase N/A

Swiss Multiple Sclerosis Cohort-Study

The key aims of the Swiss Multiple Sclerosis Cohort-Study (SMSC) are To maintain a long-term cohort (>10 years) representative of the MS population currently living in Switzerland. This requires effective measures to limit drop-outs and the continuous recruitment of MS patients and To conduct a systematic follow-up with standardized, high ...

Phase N/A

PREG-MS: New England MS Pregnancy Registry

The purpose of the study is to develop a detailed pregnancy registry of patients with Multiple Sclerosis in the New England states. Women with a diagnosis of MS that are either pregnant or actively planning to become pregnant are eligible to participate. The study will solely take place through phone ...

Phase N/A

Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis

Fingolimod (Gilenya; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA) is a novel oral disease-modifying therapy that acts as a sphingosine-1-phosphate (S1P) receptor agonist and reduces the recirculation of lymphocytes to blood and peripheral tissues, including inflammatory lesions. A critical part of fingolimod therapy still remains in the screening and initiation ...

Phase N/A

Evaluation of the First Second and New Drug-Eluting Stents in Routine Clinical Practice

Consecutive patients receiving New DES without a mixture of other DES

Phase N/A

Prospective Investigation of Multiple Sclerosis in the Three Rivers Region

Research Activities: Initial Questionnaire, Questionnaire for Self-Reported Outcomes, Biological Sample Collection (Blood, Stool, Urine, Cerebrospinal fluid), Genetic Analysis, Standard Quantitative Assessment of Function, Cognitive Assessment, Neuroimaging, Biometric Sensors, and Social Network Questionnaire.

Phase N/A

Multiple Sclerosis: The Role of Mitochondrial Dysfunction in IR Resistance

Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS) and is one of the most common neurological diseases, often leading to disability of the patients. The MS pathogenesis includes vascular and inflammatory components, however recently also the role of mitochondrial dysfunction being a hot ...

Phase N/A

Combined Use of Multiple Biomarkers With Stress Testing to Detect Coronary Artery Disease

The COMBAT-CAD Study is an observational study with the aim to improve the diagnostic accuracy by a combination of stress testing with sensitive and specific biomarkers in detecting coronary artery disease or its progress. The main subjects are all patients with CAD or suspicion of CAD sent to the University ...

Phase N/A

Comparison of Two Community Based Exercise Protocols in People With Multiple Sclerosis

Multiple Sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) that affects approximately 400,000 persons in the United States, and 1,200,000 persons between 16 and 65 years of age worldwide. It is a neurodegenerative pathology which can be characterized by a course of demyelination-mediated relapses and remissions, ...

Phase N/A